- Home
- NERV vs MYNA Comparison
NERV vs MYNA Comparison
Compare NERV & MYNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- MYNA
- Stock Information
- Founded
- NERV 2007
- MYNA 2009
- Country
- NERV United States
- MYNA Germany
- Employees
- NERV N/A
- MYNA N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- MYNA
- Sector
- NERV Health Care
- MYNA
- Exchange
- NERV Nasdaq
- MYNA Nasdaq
- Market Cap
- NERV 16.0M
- MYNA 14.9M
- IPO Year
- NERV 2014
- MYNA 2021
- Fundamental
- Price
- NERV $2.23
- MYNA $0.44
- Analyst Decision
- NERV Hold
- MYNA
- Analyst Count
- NERV 1
- MYNA 0
- Target Price
- NERV $5.00
- MYNA N/A
- AVG Volume (30 Days)
- NERV 37.0K
- MYNA 2.0M
- Earning Date
- NERV 02-20-2025
- MYNA 01-28-2025
- Dividend Yield
- NERV N/A
- MYNA N/A
- EPS Growth
- NERV N/A
- MYNA N/A
- EPS
- NERV N/A
- MYNA N/A
- Revenue
- NERV N/A
- MYNA $5,957,776.00
- Revenue This Year
- NERV N/A
- MYNA $203.73
- Revenue Next Year
- NERV N/A
- MYNA $203.84
- P/E Ratio
- NERV N/A
- MYNA N/A
- Revenue Growth
- NERV N/A
- MYNA 21.89
- 52 Week Low
- NERV $2.06
- MYNA $0.33
- 52 Week High
- NERV $13.49
- MYNA $5.89
- Technical
- Relative Strength Index (RSI)
- NERV 50.40
- MYNA 37.96
- Support Level
- NERV $2.07
- MYNA $0.49
- Resistance Level
- NERV $2.39
- MYNA $0.97
- Average True Range (ATR)
- NERV 0.12
- MYNA 0.15
- MACD
- NERV -0.01
- MYNA -0.01
- Stochastic Oscillator
- NERV 48.48
- MYNA 4.32
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About MYNA Mynaric AG American Depository Shares
Mynaric AG operates in the communication equipment business sector. The company is engaged in the manufacture and sale of products and projects and the provision of services in the field of laser technology, in particular in the aerospace, telematics, and satellite services sectors. It operates in two segments: Air and Space. The space segment comprises CONDOR terminals, and the Air segment comprises HAWK terminals. The company's product portfolio consists of Optical ground stations, Air-to-ground terminals, Air-to-air terminals, Space terminals, and Custom products and subcomponents. Its applications consist of high-altitude networks, remote eyes, satellite constellations, earth observation satellites, and others. Geographically, its key revenue is derived from the United States.